Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  Ablynx    ABLX   BE0003877942

ABLYNX (ABLX)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Ablynx
Develops and produces antibodies

Ablynx NV is a is a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand.

It offers programs for inflammation, hematology, immuno-oncology, oncology, and respiratory disease.

The company was founded on July 4, 2001 and is headquartered in Ghent, Belgium.

Number of employees : 389 persons.
Sales per Businesses
20152016Delta
EUR (in Million)%EUR (in Million)%
Nanobodies76.76100%84.77100% +10.44%
Sales per Regions
20152016Delta
EUR (in Million)%EUR (in Million)%
Belgium76.76100%84.77100% +10.44%
Managers
NameAgeSinceTitle
Edwin Moses, PhD632004Chief Executive Officer & Executive Director
Peter John Fellner, PhD732013Chairman
Wim Ottevaere612006Chief Financial Officer
Antonin Rollet de Fougerolles, PhD522013Chief Scientific Officer
Robert K. Zeldin542015Chief Medical Officer
Remi Vermeiren77-Independent Non-Executive Director
Russell G. Greig, PhD642012Independent Non-Executive Director
Bo Jesper Hansen MD, PhD592013Independent Non-Executive Director
William John Jenkins, MD702013Independent Non-Executive Director
Catherine Moukheibir, MBA572013Independent Non-Executive Director
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 61,419,295 55,282,909 90.0% 0 0.0% 90.0%
Shareholders
NameEquities%
Van Herk Investments BV 6,136,386 9.99%
Fidelity Management & Research Co. 4,576,954 7.45%
Perceptive Advisors LLC 2,773,439 4.52%
GAM International Management Ltd. 2,408,585 3.92%
Consonance Capital Management LP 2,207,243 3.59%
C.H. Boehringer Sohn AG & Co. KG 2,142,857 3.49%
OppenheimerFunds, Inc. 1,734,184 2.82%
AXA Investment Managers UK Ltd. 1,179,445 1.92%
CAPFI DELEN Asset Management SA 626,163 1.02%
JPMorgan Asset Management (UK) Ltd. 576,983 0.94%
Markets and indexes
- Euronext Brussels
- Compartiment B
- BEL Mid / Next 150, Next Biotech, PEA, Tech 40
Stock Exchange Codes
- Bloomberg Code :  ABLX:BB
- Reuters Code :  ABLX.BR
- Datastream Code :  
Company contact information
Ablynx
Technologiepark 21
BE-9052 Zwijnaarde, Gent, Oost-Vlaanderen
Belgium

Phone : +32 (0)9 262 00 00
Fax : +32 (0)9 262 00 01
Internet : http://www.ablynx.com
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalization (M$)
ABLYNX63.99%1 206
INCYTE CORPORATION14.00%24 562
QUINTILES IMS HOLDINGS INC31.30%21 366
LONZA GROUP64.29%20 140
CELLTRION, INC.--.--%19 069
ALNYLAM PHARMACEUTICALS, INC.228.53%11 181
SEATTLE GENETICS, INC.19.39%8 995
QIAGEN NV19.08%7 968
ALKERMES PLC-9.52%7 798
IONIS PHARMACEUTICALS INC23.56%7 604
ICON PLC53.83%6 252
INC RESEARCH HOLDINGS INC4.09%5 772
EXACT SCIENCES CORPORATION254.87%5 621
CHARLES RIVER LABORATORIES INTL. INC48.21%5 429
PRA HEALTH SCIENCES INC48.97%5 223
UNITED THERAPEUTICS CORPORATION-15.98%5 204
GALAPAGOS41.25%5 194
PUMA BIOTECHNOLOGY INC305.05%4 619
BIO-TECHNE CORP18.30%4 582
ACADIA PHARMACEUTICALS INC.22.75%4 419
FIBROGEN INC155.84%4 304
Connections : Ablynx
eTheRNA immunotherapies NV
Zinner NV
Azanta A/S
Edinburgh BioQuarter
AlloCyte Pharmaceuticals AG
Scottish Science Advisory Council
Mint Solutions Holding BV
LABORIE Medical Technologies, Inc.
Wellington Partners GmbH
MedDay Pharmaceuticals SAS
Allecra Therapeutics GmbH
Laboratoris Sanifit SL
William Jenkins Pharma Consulting
AM-Pharma BV
Creabilis Therapeutics SRL
Pro Vives Vzw
MipSalus ApS
Orphazyme ApS
© 2017 People , Fundamentals and Ownership    © 2017 Cofisem